The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
|Actual Study Start Date :||August 28, 2020|
|Actual Primary Completion Date :||March 5, 2021|
|Estimated Study Completion Date :||February 14, 2023|